<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-type="olc" bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-ELL23616-CPG-DS-6MH"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 S3193 IS: Telehealth Response for E-prescribing Addiction Therapy Services Act</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2023-11-01</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>118th CONGRESS</congress><session>1st Session</session><legis-num>S. 3193</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20231101">November 1, 2023</action-date><action-desc><sponsor name-id="S316">Mr. Whitehouse</sponsor> (for himself, <cosponsor name-id="S288">Ms. Murkowski</cosponsor>, <cosponsor name-id="S327">Mr. Warner</cosponsor>, <cosponsor name-id="S396">Mrs. Blackburn</cosponsor>, <cosponsor name-id="S385">Ms. Cortez Masto</cosponsor>, <cosponsor name-id="S384">Mr. Tillis</cosponsor>, <cosponsor name-id="S362">Mr. Kaine</cosponsor>, <cosponsor name-id="S372">Mrs. Capito</cosponsor>, <cosponsor name-id="S311">Ms. Klobuchar</cosponsor>, <cosponsor name-id="S406">Mr. Kelly</cosponsor>, and <cosponsor name-id="S370">Mr. Booker</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSHR00">Committee on Health, Education, Labor, and Pensions</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment, and for other purposes.</official-title></form><legis-body style="OLC" display-enacting-clause="yes-display-enacting-clause" id="H335F4E3F1C0D4ED3A93CF5AEFB27AED2"><section section-type="section-one" id="H8C2499041C00436BA272EF9BCAC55AF8"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Telehealth Response for E-prescribing Addiction Therapy Services Act</short-title></quote> or the <quote><short-title>TREATS Act</short-title></quote>.</text></section><section id="HFC2929B025D4457B82B96DD5AA4FE5DA"><enum>2.</enum><header>Telehealth for substance use disorder treatment</header><text display-inline="no-display-inline">Section 309(e)(2) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/829">21 U.S.C. 829(e)(2)</external-xref>) is amended—</text><paragraph id="H5AFECA0022634114A991D680F7AB3A23"><enum>(1)</enum><text>in subparagraph (A)(i)—</text><subparagraph commented="no" display-inline="no-display-inline" id="id63c405318bca4221a70130389de0f10c"><enum>(A)</enum><text display-inline="yes-display-inline">by striking <quote>at least 1 in-person medical evaluation</quote> and inserting the following: </text><quoted-block style="OLC" display-inline="yes-display-inline" id="idB78595A9E4044636B5613BEEB24F1729"><text>at least—</text><subclause id="H36A0762E95704A67B6B3CE0F98B8DA81"><enum>(I)</enum><text display-inline="yes-display-inline">1 in-person medical evaluation</text></subclause><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id10bcbdbe9bc448c4b9939b1625300517"><enum>(B)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="id69EA609056D745918C8F0EE0A6AB5797"><subclause commented="no" display-inline="no-display-inline" id="idbe9547e19dbc490199059b4342feff5c"><enum>(II)</enum><text display-inline="yes-display-inline">for purposes of prescribing a controlled substance in schedule III, IV, or V that has been approved by the Food and Drug Administration for the treatment of a substance use disorder, 1 telehealth evaluation of the patient; or </text></subclause><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="H311C53D146234A369BD0E0566098CF31"><enum>(2)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="id81B8CB5AE1D44F92A483AE2CCECDC7E8"><subparagraph id="id51451DBA2935471BA43A305B441BD595"><enum>(D)</enum><text display-inline="yes-display-inline">The term <term>telehealth evaluation</term> means a medical evaluation that is conducted in accordance with applicable Federal and State laws by a practitioner (other than a pharmacist) who is at a location remote from the patient and is communicating with the patient, or a practitioner who is treating the patient, using a telecommunications system referred to in section 1834(m) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395m">42 U.S.C. 1395m(m)</external-xref>) that includes audio-only or audio and video equipment permitting two-way, real-time interactive communication between the distant site practitioner and the patient, or the practitioner who is treating the patient.</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section></legis-body></bill> 

